Gilead Sciences 3Q 2026: Revenue $8.3B, Net income $2.43B, EPS $1.94— 10-Q Summary
Gilead Sciences reported 3Q 2026 revenue of $8.3B, up 6.8% YoY, with net income of $2.43B (down 20.4%) and EPS of $1.94 (down 20.2%). Growth in HIV, Trodelvy, and Livdelzi offset declines in Veklury and cell therapy sales. The company completed acquisitions and received FDA approvals for Bixlenvo and Hepcludex.
How this was made
The 30-second read
Why it matters
Mixed earnings results suggest near‑term stock pressure but long‑term growth potential from pipeline and acquisitions.
Market read
First‑report earnings release for a large‑cap biotech, providing fresh data for traders.
What to watch
Expansion of Trodelvy first‑line approvals and pipeline acquisitions may drive future growth.
Background
The article summarizes Gilead's Q3 2026 10‑Q filing, highlighting revenue, profit, product performance, and recent acquisitions.
Ticker impact
Gilead Sciences reported Q3 2026 results with revenue up 6.8% YoY but net income and EPS down ~20%, indicating a mixed earnings surprise.
likely downside as the market prices in the earnings miss
Revenue beat is modest while net income and EPS fell sharply, suggesting weaker profitability than expected.
Market effects
HIV and oncology segments may see re‑rating; competitors could benefit from Gilead's profit decline.
US biotech sector may face short‑term pressure.
Limited to pharma/biotech investors.
Counterpoint
Revenue growth and new approvals could support a longer‑term upside despite short‑term earnings miss.
Key entities
- companyGilead Sciences
US‑listed biopharma company (ticker GILD).
